Last reviewed · How we verify
Oral Methamphetamine
Methamphetamine is a sympathomimetic amine that increases the release and blocks the reuptake of dopamine and norepinephrine in the central nervous system.
Methamphetamine is a sympathomimetic amine that increases the release and blocks the reuptake of dopamine and norepinephrine in the central nervous system. Used for Attention-deficit/hyperactivity disorder (ADHD), Narcolepsy, Obesity (historical use, now rarely prescribed).
At a glance
| Generic name | Oral Methamphetamine |
|---|---|
| Also known as | Desoxyn |
| Sponsor | University of California, San Francisco |
| Drug class | Sympathomimetic amine; central nervous system stimulant |
| Target | Dopamine transporter (DAT), norepinephrine transporter (NET), serotonin transporter (SERT) |
| Modality | Small molecule |
| Therapeutic area | Psychiatry/Neurology |
| Phase | FDA-approved |
Mechanism of action
Methamphetamine acts as a potent stimulant by enhancing the activity of catecholamine neurotransmitters, particularly dopamine and norepinephrine. It increases their synaptic concentration through both promoting release from presynaptic terminals and inhibiting their reuptake. This results in increased alertness, wakefulness, and appetite suppression.
Approved indications
- Attention-deficit/hyperactivity disorder (ADHD)
- Narcolepsy
- Obesity (historical use, now rarely prescribed)
Common side effects
- Insomnia
- Nervousness or anxiety
- Headache
- Tachycardia
- Hypertension
- Decreased appetite
- Tremor
Key clinical trials
- Feasibility of Long-term, High-dose Stimulant for Methamphetamine Use Disorder (PHASE2)
- Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder (PHASE3)
- Clinical Trial of High Dose Lisdexamfetamine and Contingency Management in MA Users (PHASE2)
- Pilot Study of the Effect of Ibudilast on Neuroinflammation in Methamphetamine Users (PHASE2)
- Methamphetamine and Troriluzole (EARLY_PHASE1)
- Study of the Safety and Feasibility of Psilocybin in Adults With Methamphetamine Use Disorder (PHASE1)
- Safety and PK Study of BICX104 With or Without Bupropion Compared to Vivitrol (PHASE1)
- Intermittent Oral Naltrexone Enhanced With an Ecological Momentary Intervention for Methamphetamine-using MSM (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |